Provided by Tiger Fintech (Singapore) Pte. Ltd.

Biocryst Pharmaceuticals

8.49
+0.05000.59%
Volume:905.88K
Turnover:7.68M
Market Cap:1.77B
PE:-19.74
High:8.59
Open:8.34
Low:8.28
Close:8.44
Loading ...

BioCryst Pharmaceuticals Q4 Net Income USD -26.795 Million VS. Ibes Estimate USD -13.2 Million

THOMSON REUTERS
·
24 Feb

BioCryst Pharmaceuticals Inc - Expects to Approach Quarterly Positive EPS and Positive Cash Flow in the Second Half of 2025

THOMSON REUTERS
·
24 Feb

BioCryst Pharmaceuticals Inc - Expects to Be Profitable on an EPS Basis, With Positive Cash Flow, for Full Year 2026

THOMSON REUTERS
·
24 Feb

BioCryst Pharmaceuticals Inc Outlook 2025 Total Revenue $560 Mln - $575 Mln

THOMSON REUTERS
·
24 Feb

BRIEF-Biocryst Announces Positive Results Orladeyo® In Pediatric Patients With Hereditary Angioedema

Reuters
·
24 Feb

BIOCRYST ANNOUNCES POSITIVE RESULTS FROM APEX-P TRIAL FOR ORLADEYO® (BEROTRALSTAT) IN PEDIATRIC PATIENTS WITH HEREDITARY ANGIOEDEMA AGED 2 TO <12 Years

THOMSON REUTERS
·
24 Feb

BioCryst Pharmaceuticals Inc - Orladeyo Safe and Well Tolerated in Pediatric Hae Trial

THOMSON REUTERS
·
24 Feb

BioCryst Announces Positive Results from APeX-P Trial for ORLADEYO® (berotralstat) in Pediatric Patients with Hereditary Angioedema Aged 2 to <12 Years

GlobeNewswire
·
24 Feb

BioCryst to Present at Upcoming Investor Conferences

GlobeNewswire
·
19 Feb

BioCryst Pharmaceuticals (BCRX) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

Zacks
·
17 Feb

BioCryst Says Orladeyo Recommended for Hereditary Angioedema Prevention in Portugal

MT Newswires Live
·
12 Feb

BioCryst launches ORLADEYO in Portugal

TIPRANKS
·
12 Feb

BioCryst Pharmaceuticals Inc: Launches Orladey (Berotralstat) in Portugal

THOMSON REUTERS
·
12 Feb

Exploring Three High Growth Tech Stocks In The United States

Simply Wall St.
·
10 Feb

BioCryst to Present New ORLADEYO® (berotralstat) Results from APeX-P Pediatric Trial at 2025 American Academy of Allergy, Asthma & Immunology / World Allergy Organization Joint Congress

GlobeNewswire
·
10 Feb

BioCryst to Report Fourth Quarter 2024 Financial Results on February 24

GlobeNewswire
·
10 Feb

BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

THOMSON REUTERS
·
04 Feb

BioCryst Pharmaceuticals Price Target Maintained With a $18.00/Share by JMP Securities

Dow Jones
·
01 Feb

BioCryst (BCRX) Gets a Buy from RBC Capital

TIPRANKS
·
23 Jan

BioCryst price target raised to $12 from $10 at Evercore ISI

TIPRANKS
·
13 Jan